EE200200534A - Torasemiidi amorfne modifikatsioon, selle valmistamine ja kasutamine soolade saamiseks ning seda sisaldav farmatseutiline preparaat - Google Patents

Torasemiidi amorfne modifikatsioon, selle valmistamine ja kasutamine soolade saamiseks ning seda sisaldav farmatseutiline preparaat

Info

Publication number
EE200200534A
EE200200534A EEP200200534A EEP200200534A EE200200534A EE 200200534 A EE200200534 A EE 200200534A EE P200200534 A EEP200200534 A EE P200200534A EE P200200534 A EEP200200534 A EE P200200534A EE 200200534 A EE200200534 A EE 200200534A
Authority
EE
Estonia
Prior art keywords
preparation
torasemide
salts
pharmaceutical
amorphous modification
Prior art date
Application number
EEP200200534A
Other languages
English (en)
Estonian (et)
Inventor
Filic Darko
Dumic Miljenko
Klepic Bozena
Danilovski Aleksandar
Tudja Marijan
Original Assignee
Pliva D.D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva D.D. filed Critical Pliva D.D.
Publication of EE200200534A publication Critical patent/EE200200534A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
EEP200200534A 2000-03-20 2000-05-02 Torasemiidi amorfne modifikatsioon, selle valmistamine ja kasutamine soolade saamiseks ning seda sisaldav farmatseutiline preparaat EE200200534A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HR20000162A HRP20000162B1 (en) 2000-03-20 2000-03-20 Amorphous torasemide modification
PCT/HR2000/000011 WO2001070694A1 (en) 2000-03-20 2000-05-02 Amorphous torasemide modification

Publications (1)

Publication Number Publication Date
EE200200534A true EE200200534A (et) 2004-04-15

Family

ID=10947070

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200534A EE200200534A (et) 2000-03-20 2000-05-02 Torasemiidi amorfne modifikatsioon, selle valmistamine ja kasutamine soolade saamiseks ning seda sisaldav farmatseutiline preparaat

Country Status (29)

Country Link
US (1) US6767917B1 (de)
EP (1) EP1272470B1 (de)
JP (1) JP2003528083A (de)
KR (1) KR20020093847A (de)
CN (1) CN1211368C (de)
AR (1) AR023788A1 (de)
AT (1) ATE256662T1 (de)
AU (1) AU2000241348A1 (de)
BG (1) BG107208A (de)
BR (1) BR0017175A (de)
CA (1) CA2401908A1 (de)
CZ (1) CZ20023436A3 (de)
DE (1) DE60007360T2 (de)
EA (1) EA004950B1 (de)
EE (1) EE200200534A (de)
ES (1) ES2213006T3 (de)
GE (1) GEP20043300B (de)
HR (1) HRP20000162B1 (de)
HU (1) HUP0300596A3 (de)
IL (1) IL151801A0 (de)
IS (1) IS6551A (de)
MX (1) MXPA02009210A (de)
NO (1) NO20024464L (de)
PL (1) PL357154A1 (de)
PT (1) PT1272470E (de)
SK (1) SK15092002A3 (de)
WO (1) WO2001070694A1 (de)
YU (1) YU70502A (de)
ZA (1) ZA200208309B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020025217A (ko) * 1999-08-11 2002-04-03 추후보정 토르세미드 동질이상
IN192178B (de) * 2001-08-03 2004-03-06 Ranbaxy Lab
AU2004270161A1 (en) 2003-08-28 2005-03-17 Nicox S.A. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
EP1855688A4 (de) 2005-02-24 2011-09-14 Nicox Sa Stickoxidverstärkende diuretische verbindungen, zusammensetzungen und verwendungsverfahren
CN100421662C (zh) * 2005-11-08 2008-10-01 周卓和 托拉塞米分散片及其制备方法和应用
CN104370805B (zh) * 2013-08-13 2016-09-07 天津汉瑞药业有限公司 托拉塞米化合物
CN105949115A (zh) * 2016-05-26 2016-09-21 南京正科医药股份有限公司 一种新晶型托拉塞米
CN115417810B (zh) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1477664A (en) * 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
DE3529529A1 (de) * 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
GB8816620D0 (en) 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
CN1072215C (zh) * 1995-02-22 2001-10-03 赫彻斯特药品和化学品公司 无定形吡咯他尼、吡咯他尼多晶型物,其制备方法和用途
IN182496B (de) 1996-02-20 1999-04-17 Reddy Research Foundation
HRP980532B1 (en) * 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
KR20020025217A (ko) 1999-08-11 2002-04-03 추후보정 토르세미드 동질이상

Also Published As

Publication number Publication date
WO2001070694A1 (en) 2001-09-27
KR20020093847A (ko) 2002-12-16
DE60007360T2 (de) 2004-10-07
GEP20043300B (en) 2004-02-10
EA004950B1 (ru) 2004-10-28
EP1272470B1 (de) 2003-12-17
AU2000241348A1 (en) 2001-10-03
US6767917B1 (en) 2004-07-27
DE60007360D1 (de) 2004-01-29
JP2003528083A (ja) 2003-09-24
PT1272470E (pt) 2004-05-31
CZ20023436A3 (cs) 2003-03-12
CA2401908A1 (en) 2001-09-27
IS6551A (is) 2002-09-17
NO20024464L (no) 2002-09-20
MXPA02009210A (es) 2004-09-06
ZA200208309B (en) 2003-10-15
BG107208A (bg) 2003-07-31
YU70502A (sh) 2006-01-16
HUP0300596A2 (hu) 2003-07-28
SK15092002A3 (sk) 2003-05-02
PL357154A1 (en) 2004-07-12
BR0017175A (pt) 2002-12-10
NO20024464D0 (no) 2002-09-18
WO2001070694A8 (en) 2002-03-21
AR023788A1 (es) 2002-09-04
ES2213006T3 (es) 2004-08-16
EP1272470A1 (de) 2003-01-08
CN1211368C (zh) 2005-07-20
HUP0300596A3 (en) 2005-08-29
ATE256662T1 (de) 2004-01-15
HRP20000162A2 (en) 2001-12-31
IL151801A0 (en) 2003-04-10
CN1452613A (zh) 2003-10-29
EA200201003A1 (ru) 2003-02-27
HRP20000162B1 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
EE200300587A (et) Vedel farmatseutiline kompositsioon, selle valmistamise meetod ja kasutamine
EE200300171A (et) Kristalliline monohüdraat, meetodid selle valmistamiseks ja selle kasutamine farmatseutilise kompositsiooni valmistamiseks
EE200300236A (et) 1,2-difenüülasetidinoonid, nende kasutamine, ravim ja selle valmistamismeetod
AU2001277741A1 (en) 2-aminopyridine compounds and use thereof as drugs
NO20024175D0 (no) Azetidinderivater, deres fremstilling og farmasöytiske forbindelser inneholdende de samme
EE05183B1 (et) Asabitsklilised hendid, nende valmistamine ja kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon
LTPA2014005I1 (lt) Chinazolidino dariniai, minėtus junginius turintys vaistai, jų panaudojimas ir jų gavimo būdas
EE05232B1 (et) Reguleeritud vabastamisega graanul, meetod selle valmistamiseks ning seda sisaldav mitmehikuline ravimvorm
EE05475B1 (et) Superantigeeni sisaldav konjugaat, konjugaadi kasutamine ja konjugaati sisaldav farmatseutiline kompositsioon
HUP0303103A3 (en) Fused pyrrolocarbazoles, pharmaceutical compositions containing them and use of the compounds
EE200200484A (et) Väikeseannuseline entekaviiripreparaat ja selle kasutamine
EE200300327A (et) Uurea derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutiline kompositsioon
EE03613B1 (et) Omeprasooli naatriumisool,selle valmistamise protsess,seda sisaldav ravimkoostis ja selle kasutamine seedetrakti häirete ravimiseks
EE200100391A (et) Peptidüül-heterotsüklilised ketoonid, nende kasutamine ja farmatseutiline kompositsioon
EE05286B1 (et) Perindopriili tert-butlamiinsoola kristalliline kamma-vorm, protsess selle valmistamiseks ning seda sisaldavad farmatseutilised kompositsioonid
EE05020B1 (et) Glburiidi ravimkoostis
EE200200617A (et) (Tio)karbamiidi derivaat, seda sisaldav farmatseutiline preparaat, selle valmistamine ning kasutamine VIIa-teguri inhibiitorina
DK1282616T3 (da) Hydroxyphenylpiperidin-4-ylidenmethylbenzamidderivater til behandling af smerter
EE04490B1 (et) Ühend, selle valmistamise meetod ning kasutamine meditsiinis
DE60109530D1 (de) Amorphe Mupirocin enthaltende Arzneimittel
NO326689B1 (no) Pyrrolidinderivater, anvendelse derav, farmasøytisk preparat samt fremgangsmåte for fremstilling av forbindelsene
EE200300488A (et) Lipiiditaset alandava toimega bifenüülkarboksamiidühend, meetod selle valmistamiseks ning seda sisaldav ravimkompositsioon
NO20032614D0 (no) Farmasöytisk sammensetning med forbedret absorbabilitet
EE05168B1 (et) N-guanidinoalklamiid, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaat ning raviotstarbeline kasutamine
EE200200057A (et) Kasvutegurit IL-5 pärssiv asauratsiilderivaat, selle saamine ja kasutamine ravimi valmistamiseks ning seda sisaldav farmatseutiline kompositsioon

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
GB1A Change in the ownership or in the address of the owner